Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why in the world would I call Ameritrade to ask them to bill me more?? Lmao. See my previous post re: diff kinds of accts. ??
You need to go and look at your acct details again because it most certainly has been once per day for me.
In the app it only shows the 6.95 fee, but in the details, on the website, it shows the $15 clearing once per day.
If you are sure on what you have seen, I suppose there could be a difference depending on what type of acct you have. Ie: margin acct vs regular, etc.
That's not entirely accurate. There is a 6.95 trade to buy and a 6.95 trade to sell plus commission (comission has been $.23 for me up to $6.80 on my trades from 5000 shares up to 34000 shares but varies based on $ value), plus a $15 foreign trade fee PER DAY. They've only charged me the $15 once per day, even when I've had 6 or 8 in and outs. If you are moving anything above $500, then this is insignificant. Some other platforms are charging $50 per trade.
If you want to see exactly what they're charging you, just login online to the website, not the app, and click on Account Details and it will break it all down for you. On a sell, it combines the 6.95 with the commission, but the foreign transaction fee is a separate line item and always clears 2 business days after the trade.
40 mins before close for the weekend. Totally FOMO trades.
TD Ameritrade has charged my a $15 daily fee to buy and sell RLFTF (they have only charged me the $15 fee once per day no matter how many trades I do in or out), plus their normal 6.95 to buy and 6.95 plus commission to sell (usually just a couple bucks for my trades, and some of my sell orders had no commission tacked on (I almost remember them saying they were waiving them for a certain period of time?
Like a promotion during Covid back in July?)).
These fees are really insignificant, unless you're trying to buy, in really really small buckets.
Why oh why would Gem sell in the .50's, when they can wait another week and sell in the multi-dollars? I'm sorry but I'm just not buying it, and the volume is too low as well. Volume of 4.8 million total today. How much could they really be selling?
Ahhhh. You lost me at boat.
Achieving financial independence has to be amazing, but investing in companies that make the world a better place, has its own rewards. I think Relief Therapeutics may just do both for me.
My understanding is, the TD Ameritade foreign fee ($15) is a once a day fee, and going back looking at My Account Details it only charged those fees 1 time per day no matter how many trades that day and charges 2 days later as another said.
It's a foreign transaction fee and charged once per day, instead of per trade.
To the folks being disappointed lately in this stock:
did you know, that Gilead's pps actually went down in the days after Rem's approval and continued sliding for a couple weeks after. It seems a news report came out on April 29th which stated that they thought Gilead had enough data to submit and the stock price jumped on the rumor and then fell after the EUA approval actually came out on 5/1.
Like everyone else, I'm hoping for the "Trump Factor" and FOMO, however, I now have more realistic expectations for approval day. I hope I now won't be as disappointed, if things don't happen like everyone has been hyping it will on approval day (ie: 10 bagger, 20 bagger, etc). I guess, just like in politics, you have to tune out the lunatics on either side and make calm rational decisions. Now, if I'm wrong in reducing my expectations somewhat, and I sincerely hope I am wrong, then it's all gravy.
Moral: be realistic in your exit planning, but hope for the hype to exceed your expectations.
Or Blockbuster when they passed on Netflix. Doh! Bahahaha
That is making more sense. The rise already being priced in. I think I would be wise to temper my expectations a little in the future. That probably has more to do with any resentment anyone feels, after watching a lesser ticker soar, by having too high of an expectation, in a certain timeframe, in the first place.
Hearing Trump say that would definitely blast this off. It would be on every channel 24/7 making fun of him for supporting this little company until they realize it's really the answer to covid.
Agreed. I'm not expecting great movement until a major change in volume arrives. Everyone is holding long and volume has stagnated. I just hope big media picks it up and can bring in the volume. Seeing SPI blast off on nothing is frustrating though, especially when you see how amazing the RLFTF story is.
Agreed, if there wasn't Kodak and SPI to compare to. How do you explain those? We have the most perfect setup I've ever seen and I've had a margin acct. since 2002.
I am not a basher and not big on conspiracies, and usually patient, especially when it comes to the market. I am long and I love this ticker, I will hold and I do believe in the product and the Mgm't team and will wait for the big payoff; however, there is something seriously wrong when SPI has no product, no pipeline, no way to produce, and yet can run like they did, $1.08 to $46.67 in 2 days, and we move just a few pennies on excellent news.
Kodak doesn't get a grant, but gets a loan and runs from $2.13 to $60.00 in 3 days. Something is wrong and something/someone is definitely holding this one down.
Not trying to sound hysterical like a couple others on this board, but this is acting weird. I welcome anyone that can prove me wrong, but this is not behaving like it should with the PR's we have received. I'm in for the long haul, but really wish I had some insight on the why. Thoughts? Anything constructive without the normal "this is OTC, etc. etc.", that doesn't really explain anything?
https://wolfstreet.com/2020/09/23/robinhood-traders-trigger-massive-idiocy-on-scheme-by-nasdaq-listed-chinese-penny-stock-spi-energy-that-skyrocketed-4387-collapsed-by-two-thirds-in-just-one-day/
Agreed. There has to be an extreme amount of pressure from the WH to approve before the debate.
That was the 2nd one. The 1st was 22 days. (I hope it's even shorter than 14 days now.)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158436861
Wow. As of 3 trading days ago, 56% of the trades were shorts. Yesterday, 35%.
https://www.otcshortreport.com/company/RLFTF
MM games again. JANE is letting it run, but PUMA is still trying to hold it down.
For those that want to watch the Swiss: if you watch this cnbc chart, it will populate the price in real time in the chart itself, even though the price above is 15 delayed.
https://www.cnbc.com/quotes/?symbol=RLF-CH
Tiger Money, I can't reply to PM's, because I don't have a paid membership, but you may want to check out post #20803.
I get it, but I just didn't want to type it out. Already a few bad articles written lately, and we don't need anymore. I know folks on other boards read this also, because I was quoted this morning on Y.
From what I remember, it was settling at .47ish and then for no apparent reason, ran up to .57ish then went right back to trading sideways. Hmmmmmmm
I agree. PUMA & JANE up to their usual tricks, but they don't have to hold it down very hard because there is no volume.
Per this PR on 8/10/20, Gilead filed an NDA for Remdes*vir (Veklury) on 4/8/20. (Link below)
"Veklury is currently available in the U.S. under an Emergency Use Authorization for the treatment of hospitalized patients with severe COVID-19. The filing is the final tier of the rolling NDA submission that was initiated on April 8, 2020."
Approval came on 5/1/20. (Link below)
"Gilead’s Investigational Antiviral Remdesivir Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of COVID-19"
22 days for EUA. 22 days from NeuroRX's submission for Aviptadil on 9/17/20 is 10/9/20. Since the early days of Covid back in April, the FDA has worked out a lot of kinks and streamlined somewhat, so I hope we hear something sooner, but trial results and EUA is looking good for early to mid-October.
https://www.gilead.com/news-and-press/press-room/press-releases/2020/8/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-veklury-remdesivir-for-the-treatment-of-covid19
https://www.gilead.com/news-and-press/press-room/press-releases/2020/5/gileads-investigational-antiviral-remdesivir-receives-us-food-and-drug-administration-emergency-use-authorization-for-the-treatment-of-covid19
https://insideparadeplatz.ch/2020/09/21/genfer-kmu-schlaegt-big-roche-mit-covid-medi/
"The Covid crisis is a once in a lifetime opportunity for the pharmaceutical industry. The Swiss Multi Roche hits the media drum accordingly."
"But it is not the Basel people who are ahead in virus therapy. It's a small company in Geneva called Relief Therapeutics."
I don't really think they would be doing all of this, if their endgame was to sell off early to big pharma.
Well that takes away three worries. 1. What the financial agreement with NeuroRx actually looks like. 2. Will they merge. 3. Will rights be sold, excluding Relief's shareholders from future profits. All in all a very fair agreement that incentivises both sides. I read this as Relief and NeuroRx are in it for the long haul and aren't necessarily planning on selling yet. Will be losing 1/2 of the US/Canada/Israeli market, but weighted heavily in favor of Relief for the rest of the world. Good news overall as far as I'm concerned.
Did he not just set the stage for this to be approved so fast, by demanding the FDA move at warp 9? Credit for the drug? No. Credit for how it's being studied? No. But some credit for how fast it gets approved? Absolutely. The truth is, this process can take between 5-13 yrs in normal times.
Aquisition is a very likely scenario because acquisitions and Dr. Javitt go hand in hand. (Articles/bios written in different years explains varying #'s of successful acquisitions cited.) An acquisition in and of itself is not necessarily a bad thing, depending on timing. If it occurs after FDA approval, we could be big winners. If it occurs before, smaller winners.
https://orcid.org/0000-0003-2371-1609
Jonathan has been a founder of 6 health informatics and analytics companies that have gone on to successful public acquisitions: Healthcare Computer Associates (NYSE: SMSI), NextGen (Nasdaq:QSII), Certitude (NYSE:UNH), Active Health Management (NYSE:UNH), First Gateways (NYSE:DGX) and Coderyte, Inc., (NYSE:3M), and Telcare, Inc., funded by Qualcomm Ventures, Sequoia Capital, and Norwest Venture Partners. Most recently, he has founded NeuroRx, Inc., a clinical stage pharmaceutical company targeting the brain’s NMDA receptor for treatment of acute suicidal crisis in patients with depression.
https://www.neurorxpharma.com/about-us/#1595800169714-df900b26-e0f6
Dr. Javitt has played leadership roles in seven successful healthcare IT and biopharma startups with public exits. He has additionally led drug-development engagements for Merck, Allergan, Pharmacia, Novartis, and Pfizer.
https://www.crunchbase.com/person/jonathan-c-javitt
is a physician with expertise in information technology, health economics, and public health. He has been a founder of health information technology companies that have become part of Siemens, Inc., United Health Group, Inc., and Aetna, Inc. In 1994 he founded Certitude, Inc., which was acquired by United Health Care (NYSE:UNH) as part of the Ingenix formation. Following a term of service as Senior VP and National Medical Director, he left to co-found eMEDx, Inc., which became part of Active Health Management. Dr. Javitt served as Chief Scientific Officer of Active Health until its acquisition by Aetna (NYSE:AET).
He went on to serve as a member of the Office of the CEO and Chairman of FCG, Inc. as a lead architect of the Gateways offering, which was acquired by Quest Diagnostics (NYSE:DGX). He has played a leading role in pharmaceutical and medical device development teams at Merck, Allergan, Alcon, and Pfizer.
4 billion ÷ 2.5b shares is $1.60/share??? They would be insane to sell for that. The finish line is in sight.
I think Javitt saw this coming and hired the extra expert to remove any appearance of impropriety. He is always 3 moves ahead of everyone else.
Agree. Politico would've contacted all the players, prior to printing, for their comment, so the players would've known about this for some time, which definitely explains why they've been a little more tight-lipped lately.
Javitt said that an outside biostatistician is working with the committee, but is not a member of it. He also downplayed the panel’s role in the trial. “Unless there are unexpected severe adverse events to take action on, the committee doesn’t have much to do,” he said.
Supreme confidence indicated here in the outcome. If Javitt isn't worried about trial data, we shouldn't be either.
Approaching 10 day average volume (9.4m) with a lot of day left. Looks like the MM's have finally let go of the reins.
Back in the 50's!
One thing you eluded to, is nothing will be able to stop this if the trials prove out. I agree. To be honest, I've been thinking about that since the first of August and more specifically the timing. As far as hoping for a meteoric rise, I don't think any of us could have planned it any better than a few weeks before a major election during the worst pandemic ever. If the results are positive, the timing could not be more perfect than this. Trump needs this. This country needs this. The world needs this. What a perfect storm this could be. Everytime I get a little antsy, I just always keep reminding myself to be patient, but it's hard with all the negativity posted constantly and in all fairness, having a few doubts, when a lot of us have potentially life changing positions, is only natural. Even the name of the company is perfect. This will be Relief from covid.